Notably, we also observed higher levels of Th17.1 cells and their negative correlation with C3 protein levels in anti-DNA + SLE patients, thereby suggesting that Th17.1 probably contribute to a higher disease activity and worse treatment outcomes in anti-DNA+ SLE patients. Here, C3 is linked to systemic lupus erythematosus.